Company: ACBM
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001640334-25-001999
Chunk: 33

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 8
Chunk 33
---
 2024 and 2023. To date, the Company has not generated any revenue subsequent to December 31, 2022 and did not generate any products from its research and development activities. Further, the Company’s common stock is presently traded on the OTC Market Group’s Pink Limited Market.  The Company’s common stock was previously listed on the OTC Market Group’s Expert Market, as a result of which the common stock was not eligible for proprietary broker-dealer quotes.  There are no market makers for the Company’s common stock.  At present, the Company’s common stock is not eligible for proprietary broker-dealer quotations and all quotes reflect unsolicited customer orders.  Unsolicited only stocks have a higher risk of wider spreads, increased volatility, and price dislocations. Investors may have difficulty selling this stock. An initial review by a broker-dealer under SEC Rule15c2-11 is required for brokers to publish competing quotes and provide continuous market making.  Accordingly, there are no published quotes for the Company’s common stock and the Company cannot assure you that a broker-dealer will take the necessary steps to make a market in its common stock.  These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Although the Company proposes to fund operations through sales of its products and equity financing arrangements, it does not presently have any orders for products, its common stock is reported on the Expert Market as a result of which there are no market makers in the common stock and it is delinquent in its filings with the Securities and Exchange Commission, as a result of which the Company may not be able to raise funds for capital expenditures, working capital and other cash requirements and will have to rely on advances from a minority stockholder and an officer. If the Company cannot generate revenue from its products, it may not be able to continue in its business.

NOTE 4 - RELATED PARTY TRANSACTIONS AND BALANCES During the nine months ended September 30, 2025 and 2024, a minority stockholder who is not a 5% stockholder advance $2,250 and $1,000 and paid expenses of $172,522 and $25,502 on behalf of the Company, respectively. During the three months ended September 30, 2025 and 2024, such minority stockholder advance